Eleven year survival gap tied to high B12
Five years versus nearly eleven years. That is the survival difference researchers found in 2026 between colon cancer patients with very high vitamin B12 levels and those with normal levels. The gap is stark. It is not subtle. And it forces a question that scientists are only now beginning to answer: Could the vitamin we take to feel better actually be telling us something dangerous?
For decades, vitamin B12 wore a white hat. Nutritionists called it essential. Doctors prescribed it for fatigue. Health food stores sold it in bottles labeled “energy support.” The molecule, known scientifically as cobalamin, helps your body build red blood cells. It keeps your nerves firing properly. It helps your cells copy DNA each time they divide. Without enough of it, the body stumbles. Deficiency causes anemia, nerve damage, confusion, and memory loss. Vegans worry about it. Older adults watch for it. People with Crohn’s disease or celiac disease often cannot absorb it from food at all.
But the story has a second chapter. And that chapter began quietly, in labs where researchers noticed something odd: cancer patients kept showing up with unusually high B12 levels in their blood. Not from supplements. Not from diet. Just high. For no obvious reason.
A research team at the University of Copenhagen was among the first to dig into this pattern systematically [1]. They analyzed blood samples from thousands of patients. They found that elevated B12 was not rare in cancer cases. It was common enough to demand explanation. The team’s 2022 paper concluded that high B12 in cancer patients is often an “epiphenomenon.” That is a scientific way of saying: the vitamin shows up alongside the disease, but it may not cause it. The two things travel together, like a shadow and the person casting it.
The researchers proposed one mechanism. First, tumors can stress the liver. The liver stores large amounts of B12. When it is damaged or under strain, it leaks the vitamin into the bloodstream. Second, some tumors increase proteins that bind to B12 in the blood. This pushes test readings higher without meaning the body’s cells are actually using more B12. The number on the lab report goes up. But the reality inside the cells may be different.
A 2024 study from the University of Milan reached a similar conclusion. High B12 is not necessarily a driver of cancer. But it may be a sign that something is already wrong.
Then came a study from a collaborative group at the University of Oxford and the National University of Singapore [2][3]. That study tracked colon cancer patients over time. The results were concrete. Patients with very high B12 levels survived a median of around five years. Patients with normal levels survived nearly eleven years. The difference was not small. It was more than double.
Similar patterns have emerged in oral cancer. Patients with elevated B12 tend to have worse outcomes. The same holds true for patients receiving immunotherapy. High B12 correlates with poorer responses to treatment. The pattern repeats across different cancers, different countries, different populations.
But here is where the story gets tricky. Correlation is not causation. Scientists say this so often it has become a cliché. But the cliché exists because the mistake is so common. Just because high B12 appears alongside worse outcomes does not mean the vitamin caused those outcomes. The cancer itself may be causing the B12 levels to rise. The liver damage from the tumor may be the real culprit. The binding proteins may be the signal, not the vitamin itself.
A case-control study from Vietnam added another layer. Researchers found a U-shaped relationship between B12 intake and cancer risk. Both low and high intake were associated with increased risk. The sweet spot was in the middle. This is the classic pattern of a nutrient that matters, but only within a certain range. Too little harms you. Too much may also harm you. The body wants balance.
The idea that more is better is deeply embedded in how we think about vitamins. If a little is good, a lot must be better. That logic works for some things. It fails for others. Vitamin B12 supports cell growth. That is its job. But cell growth is not selective. Healthy cells use B12 to divide. Pre-cancerous cells use it too. If abnormal cells are already present in the body, flooding the system with growth-supporting nutrients could theoretically help them grow. This is a concern, not a proven fact. Proving it in humans is extraordinarily difficult. You cannot ethically give people high-dose supplements and wait to see who gets cancer.
What researchers can do is look at large populations over time. And those studies have not shown clear protective effects from high-dose B vitamins against cancer. One analysis found a reduced risk of melanoma. But that was a single finding, not a general pattern. Other observational studies have suggested a slight increase in lung cancer risk with long-term, high-dose B6 and B12 supplementation, particularly among men and smokers. Again, these studies cannot prove cause and effect. But they raise enough questions that scientists are paying attention.
The broader message is not that B12 is dangerous. It is that context matters. B12 from food is not the issue. You would have to eat enormous amounts of meat, eggs, and dairy to reach the blood levels seen in those cancer patients. Food sources are self-limiting. Your body absorbs only what it needs and excretes the rest. Supplements are different. High-dose pills deliver concentrated amounts directly. The body cannot easily flush out excess B12. It stores it. And over years, those stores can build up.
Doctors have noticed that unexplained, persistent high B12, especially in people who do not take supplements, should not be ignored. It may point to liver disease. It may point to blood disorders like polycythemia vera, where the bone marrow produces too many red blood cells. It may point to an underlying cancer that has not yet been detected. The vitamin level itself is not the problem. It is the message the level carries.
This is where the research connects to something larger. The same principle applies to other nutrients. Vitamin A in excess can cause liver damage. Vitamin D in extreme excess can cause calcium buildup in the blood. Iron overload damages organs. The body evolved to handle nutrients within certain ranges. It did not evolve to handle the megadoses that modern supplement bottles deliver.
The University of Colorado published a review in 2023 examining the effects of high-dose vitamin supplementation across multiple studies [4]. The conclusion was measured: for most people, a balanced diet provides everything needed. Supplements help those with specific deficiencies. But megadoses without medical supervision carry unknown risks.
So what should a person do? The answer is simpler than the science behind it. Eat a balanced diet. Include animal products or fortified foods if you are vegan. Get your B12 from food first. If you need a supplement because of age, diet, or a medical condition, take the recommended dose. Do not take more. Leave the megadoses on the shelf unless a doctor advises them.
Deficiency is real. It is dangerous. It causes permanent nerve damage if left untreated. That problem is better understood and more common than the problem of excess. But the existence of one risk does not eliminate the other. Both ends of the spectrum matter.
The 2026 study from Oxford and Singapore is not the final word [2][3]. It is a data point. More research will follow. Other labs will try to replicate the findings. Scientists will dig into the mechanisms. They will ask whether high B12 is a cause, a consequence, or both. They will study whether lowering B12 levels in cancer patients changes outcomes. That work is already underway at the Karolinska Institute in Sweden and at the University of Tokyo [5][6].
For now, the practical message is clear. Get enough. Not too much. And if your doctor runs a blood test and finds your B12 is high for no obvious reason, do not ignore it. Ask questions. It may be nothing. Or it may be the first clue to something that needs attention.
Vitamin B12 is not the enemy. It is essential. But it is also a signal. And signals are only useful if you read them correctly. The researchers who published the 2026 study put it plainly: unexplained high B12 should not be dismissed. It is a flag. Whether that flag marks a battle already underway or a warning of one to come is the question the next decade of research will answer.
The numbers from 2026 will be tested. The five-year versus eleven-year survival gap will be examined in larger populations. New studies will refine the estimate. But the gap exists. It is real. And it changes the story of a vitamin we thought we understood.
By 2030, clinical guidelines may include B12 levels as part of cancer screening protocols. By 2035, targeted therapies may use B12 as a marker for treatment response. The research is moving fast. The implications are still unfolding.
For now, the advice is straightforward. Eat well. Supplement wisely. And remember that more is not always better. The body knows balance. It has known it for millions of years. The challenge is learning to listen.